Pacific biosciences of california inc
PACB 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
PACB 近期報酬表現
4.29%
Pacific biosciences of california inc
-0.98%
同產業平均
-0.22%
S&P500
與 PACB 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
TXG | 10x genomics inc | 2 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
ADPT | Adaptive biotechnologies corp | 4 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
EXAS | Exact sciences corporation | 2 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
TWST | Twist bioscience corp | 3 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
VCYT | Veracyte inc | 3 分 | 1 分 | 2 分 | 2 分 | 1 分 |
- TXG 10x genomics inc價值 2 分趨勢 1 分波段 2 分籌碼 3 分股利 1 分查看更多
PACB 公司資訊
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding (SBB) short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. It has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which accurately detects the nucleotide sequence and epigenetic status of individual DNA molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.